Press Release September 20, 2016

Teva and Regeneron Start Global Collaboration for Fasinumab with $250 Million Upfront Payment

Goodwin represented longtime client Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) in its announced global agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to develop and commercialize fasinumab, an investigational novel nerve growth factor antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global commercial value, as well as ongoing research and development costs of approximately $1 billion.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.

The Goodwin team advising Teva was led by partner Kingsley Taft (Life Sciences) and associates Christine Walchuk, Erini Svokos, and Jennifer Ford in corporate and licensing matters and partner Marta Delsignore (Intellectual Property), counsel Lindsey Wanner, law clerks Vi Tran and Beth Ashbridge, and science advisor Matthew Miner in intellectual property matters.

For more information on the transaction, please view the joint press release.